| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Citi |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2009-03-09 09:47:02 |
| Versijas komentārs | |
| Teksts |
JSC „Grindeks” informs that it continues negotiations with Byelorussian Pharmaceutical Company RUE “Borisov Medical Preparations Plant” (РУП "Борисовский завод медицинских препаратов") regarding possible investment project. “Grindeks” notes, that statements in the “Business&Baltics” publication (09-03-2009) ““Grindeks” shopping trip to Byelorussia” on terms of the deal are considered aproximate. Assestment of the Byelorussian Pharmaceutical Company is in process and only after the completion of that JSC “Grindeks” will confirm its participation in the investment project. About “Grindeks” JSC “Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development and manufacturing of original products, generics and active pharmaceutical ingredients. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. “Grindeks” concern consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, USA. The shares of JSC „Grindeks” are listed in the Official List of „NASDAQ OMX Riga”. You are kindly invited to www.grindeks.lv to get to know more about our company! Contacts: Laila Kļaviņa Head of the Communications Department JSC “Grindeks” Phones: +371 67083370, + 371 29256012 e-mail: laila.klavina@grindeks.lv |
| Pielikumi |
|